Early hematopoietic stem cell transplantation for cerebral X-linked adrenoleukodystrophy — the allogeneic HCT for ABCD1 mutation-related childhood cerebral demyelination before advanced neurologic decline representing the fastest-growing treatment standard in the global X-ALD therapeutic landscape — creates the most clinically decisive market segment, with the X-Linked...